Oncology

News

Nuvation Bio nears commercial stage with AnHeart buy

Nuvation Bio has accelerated its development into a commercial-stage biotech with a deal to acquire AnHeart Therapeutics and its late-stage lung cancer therapy taletrectin

News

FDA turns down Regeneron bispecific blood cancer antibody

The FDA has turned down a pair of marketing applications for Regeneron’s CD20xCD3 bispecific antibody odronextamab to treat two common forms of non-Hodgkin lymphoma (NHL).

News

Clasp Therapeutics chief executive Rob Ross

Clasp emerges with $150m for safer T-cell engagers

Clasp Therapeutics has burst onto the T-cell engager (TCE) scene with $150 million in funding for a platform that aims to improve the safety of the class, which is current

News

Iclusig gets FDA nod as frontline therapy for rare leukaemia

Takeda’s Iclusig has become the first targeted therapy approved by the FDA for use alongside chemotherapy as a first-line therapy for a rare form of acute lymphoblastic le

News

AZ agrees $2bn deal to buy radiopharma firm Fusion

AstraZeneca has upgraded a 2020 alliance with Fusion Pharma focusing on radioconjugate therapies for cancer, opting to buy the firm outright in a deal worth around $2 bill

News

OS data set up wider Jemperli use in endometrial cancer

GSK’s Jemperli has claimed an edge over its main rival in the endometrial cancer therapy market after showing improved overall survival in a broad patient population in th

Nuvation Bio nears commercial stage with AnHeart buy

FDA turns down Regeneron bispecific blood cancer antibody

Clasp emerges with $150m for safer T-cell engagers

Iclusig gets FDA nod as frontline therapy for rare leukaemia

AZ agrees $2bn deal to buy radiopharma firm Fusion

OS data set up wider Jemperli use in endometrial cancer

Biotech is back, with Craig Ackerman

Using AI-driven synthetic personas to take your insights fur...

Oncology

Editor's Picks